Patents by Inventor David Satijn

David Satijn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20260151500
    Abstract: The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer).
    Type: Application
    Filed: January 30, 2026
    Publication date: June 4, 2026
    Inventors: Reshma Abdulla RANGWALA, Esther Cornelia Wilhelmina BREIJ, David SATIJN, Sandra VERPLOEGEN, Jantine BAKEMA, Oyewale O. ABIDOYE, Leonardo Viana NICACIO, Andreas LINGNAU
  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 12637515
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: May 26, 2026
    Assignee: GENMAB A/S
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz, Edward Van Den Brink, Dennis Verzijl
  • Antibodies binding AXL
    Patent number: 12589150
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: March 31, 2026
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20260085126
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: August 27, 2025
    Publication date: March 26, 2026
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 12570751
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: March 10, 2026
    Assignees: Genmab A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz, Edward Van Den Brink, Dennis Verzijl
  • ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4
    Publication number: 20260028427
    Abstract: The present invention relates to a multispecific antibody comprising at least a FAP? binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: June 5, 2025
    Publication date: January 29, 2026
    Inventors: Bart E.C.G. DE GOEIJ, IIse Jongerius, Grietje Andringa, Madelon Paauwe, Theodorus Sjouke Plantinga, David Satijn, Jamila Laoukili, Onno Wouter Kranenburg, Marije Overdijk
  • ANTIBODIES
    Publication number: 20250340647
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 3, 2025
    Publication date: November 6, 2025
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W. BREIJ
  • ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20250333527
    Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: February 25, 2025
    Publication date: October 30, 2025
    Inventors: Kristel Kemper, Maarten van der Kroef, Dennis Verzijl, Andrea Gorlani, Pauline Linda de Goeje, Lars Guelen, David Satijn, Esther C. W. Breij, Ugur Sahin, Sina Fellermeier-Kopf, Maren Köhne
  • ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20250333526
    Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: February 25, 2025
    Publication date: October 30, 2025
    Inventors: Kristel Kemper, Maarten van der Kroef, Dennis Verzijl, Andrea Gorlani, Pauline Linda de Goeje, Lars Guelen, David Satijn, Esther C. W. Breij, Ugur Sahin, Sina Fellermeier-Kopf, Maren Köhne
  • BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY
    Publication number: 20250325643
    Abstract: The present invention provides combination therapy using a first binding agent comprising at least one binding region binding to CD27 in combination with a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137 to reduce progression or prevent progression of a tumor or treating cancer.
    Type: Application
    Filed: May 12, 2023
    Publication date: October 23, 2025
    Inventors: Esther C. W. BREIJ, Ugur SAHIN, Isil ALTINTAS, Andreea IOAN, Frank BEURSKENS, Rob N. DE JONG, Janine SCHUURMAN, Pauline Linda DE GOEJE, David SATIJN, Peter BOROSS, Andrea IMLE, Kristina NÜRMBERGER, Alexander MUIK, Friederike GIESEKE
  • Binding agents that bind OX40 (CD134) and method of use thereof to treat disease
    Patent number: 12421319
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Grant
    Filed: October 5, 2023
    Date of Patent: September 23, 2025
    Assignees: BIONTECH SE, GENMAB A/S
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20250289899
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 3, 2025
    Publication date: September 18, 2025
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20250289900
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 3, 2025
    Publication date: September 18, 2025
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • Antibodies capable of binding to OX40, variants thereof and uses thereof
    Patent number: 12410258
    Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: May 10, 2024
    Date of Patent: September 9, 2025
    Assignees: Ganmab A/S, BioNTech SE
    Inventors: Kristel Kemper, Maarten van der Kroef, Dennis Verzijl, Andrea Gorlani, Pauline Linda de Goeje, Lars Guelen, David Satijn, Esther C. W. Breij, Ugur Sahin, Sina Fellermeier-Kopf, Maren Köhne
  • Antibodies binding to fibroblast activation protein alpha and death receptor 4
    Patent number: 12351650
    Abstract: The present invention relates to a multispecific antibody comprising at least a FAP? binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: June 26, 2024
    Date of Patent: July 8, 2025
    Assignee: GENMAB A/S
    Inventors: Bart E.C.G. De Goeij, Ilse Jongerius, Grietje Andringa, Madelon Paauwe, Theodorus Sjouke Plantinga, David Satijn, Jamila Laoukili, Onno Wouter Kranenburg, Marije Overdijk
  • ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4
    Publication number: 20250002610
    Abstract: The present invention relates to a multispecific antibody comprising at least a FAP? binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: June 26, 2024
    Publication date: January 2, 2025
    Inventors: Bart E.C.G. De Goeij, Ilse Jongerius, Grietje Andringa, Madelon Paauwe, Theodorus Sjouuke Plantinga, David Satijn, Jamila Laoukili, Onno Wouter Kranenburg, Marije Overdijk
  • ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20240400703
    Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: May 10, 2024
    Publication date: December 5, 2024
    Inventors: Kristel Kemper, Maarten van der Kroef, Dennis Verzijl, Andrea Gorlani, Pauline Linda de Goeje, Lars Guelen, David Satijn, Esther C. W. Breij, Ugur Sahin, Sina Fellermeier-Kopf, Maren Köhne
  • ANTIBODIES
    Publication number: 20240392032
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 26, 2024
    Publication date: November 28, 2024
    Inventors: David SATIJN, Esther C.W. Breij, Bart E.C.G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20240376221
    Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: May 10, 2024
    Publication date: November 14, 2024
    Inventors: Kristel Kemper, Maarten van der Kroef, Dennis Verzijl, Andrea Gorlani, Pauline Linda de Goeje, Lars Guelen, David Satijn, Esther C. W. Breij, Ugur Sahin, Sina Fellermeier-Kopf, Maren Köhne
  • ANTIBODIES AGAINST PD-L1
    Publication number: 20240317861
    Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: December 14, 2023
    Publication date: September 26, 2024
    Inventors: Isil ALTINTAS, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rik RADEMAKER, Paul PARREN, Bart DE GOEIJ